newsfilter
← Latest News
PR Newswire·

Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market

LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that